美法庭裁定强生就镇痛药滥用危机支付逾5.7亿美元
美国奥克拉荷马州法官下令强生(Johnson & Johnson)支付5.72亿美元,就鸦片类药危机引发州政府开支上升承担责任,但数额显着少於市场预期。该州检察官在诉讼中要求强生赔偿170亿美元,市场预期罚款额为15亿至20亿美元。强生表明会就裁决上诉。
法官认为强生在推广芬太尼及Nucynta镇痛药时误导,并造成公众问题。奥克拉荷马州政府要求强生未来30年协助处理有关问题,包括资助除瘾及预防项目。
根据美国疾病控制及预防中心数据,该等含吗啡作用的镇痛药被滥用,导致1999年至2017年期间近40万人死亡,其中在奥克拉荷马州已有6,000宗。目前约有2,500宗地方政府就该等药物滥用事件向药厂索偿的诉讼,奥克拉荷马州的诉讼为首宗开庭个案,部分药厂选择进行和解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.